<DOC>
	<DOCNO>NCT00003044</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving drug different way may kill tumor cell . PURPOSE : Phase II trial study effectiveness cisplatin epinephrine administer directly tumor treat patient primary liver cancer remove surgery .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate safety efficacy cisplatin-epinephrine injectable gel ( Intradose MPI-5010 ) patient unresectable primary hepatocellular carcinoma . OUTLINE : This open label , two stage , multicenter study . Patients receive intratumoral treatment ciplatin-epinephrine ( MPI-5010 ) weekly , four treatment within six week period , follow evaluation two week last treatment . Immediately first course , optional second course treatment may undertake discretion investigator . Patients complete response , partial response , and/or increase necrosis least 30 % total treated tumor volume follow monthly 6 month . At completion 6 month follow follow documentation disease progression development new tumor , patient monitor survival extend follow period . All nonresponders last 2 week posttreatment evaluation enter extend follow monitor monthly survival . PROJECTED ACCRUAL : Up 55 patient accrue study .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove unresectable primary hepatocellular carcinoma No major vessel involvement Disease must confine liver ( extrahepatic disease ) Patients 3 tumor , tumor exceed 7 cm diameter , sum total tumor volume le 200 cm3 PATIENT CHARACTERISTICS : Age : 18 Performance Status : Karnofsky 40100 % Life Expectancy : At least 4 month Hematopoietic : Hemoglobin least 10 g/dL Platelet count least 75,000/mm3 Absolute granulocyte count least 1,000/mm3 PT within 3 second institutional norm Hepatic : SGPT great 3 time upper limit normal ( ULN ) SGOT great 3 time ULN ChildPugh grade A B Albumin least 25 g/L Bilirubin great 2.98 mg/dL Absent easily control ascites require routine intermittent paracentesis Alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 1.3 time ULN OR Creatinine clearance least 45 mL/min Cardiovascular : No coronary artery disease No New York Heart Association class III great cardiac symptom Other : Not pregnant nursing No medical psychiatric condition compromise informed consent No obesity tumor location would limit adequate tumor image No history bleed liver tumor ( ) gastroesophageal bleed No known hypersensitivity cisplatin , bovine collagen , epinephrine , sulfites radiographic contrast agent No history encephalopathy PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy hepatocellular carcinoma No concurrent immunomodulating agent Chemotherapy : No prior concurrent chemotherapy hepatocellular carcinoma No concurrent cytotoxic agent Endocrine therapy : No prior endocrine therapy hepatocellular carcinoma Radiotherapy : No prior radiotherapy hepatocellular carcinoma Surgery : Prior surgical resection liver allow Other : No concurrent use aspirin , nonsteroidal antiinflammatory agent , anticoagulant include warfarin sodium ( Coumadin ) , epinephrine contain medication include topical anesthetic bupivacaine HCl No prior investigational agent within 4 week study No concurrent use probenecid thiazide Concurrent use analgesic antiemetic allow Concurrent use topical local anesthetic , locoregional nerve block , systemic agent allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>localize unresectable adult primary liver cancer</keyword>
</DOC>